米力农注射液治疗肺心病合并呼吸衰竭患者的临床疗效

Clinical efficacy of milrinone injection in the treatment of pulmonary heart disease complicated with respiratory failure

目的探讨采用米力农注射液综合治疗肺心病合并呼吸衰竭患者的临床疗效,并观察其对患者血气指标、血液黏稠度及肺动脉压的影响。方法回顾性分析2014年4月～2016年4月浙江金华广福医院收治的100例肺心病合并呼吸衰竭患者患者临床资料,给予常规吸氧、利尿、平喘及抗感染等治疗者为对照组;对照组治疗基础上采用米力农注射液治疗者为治疗组,每组50例。比较组患者临床疗效及不良反应,并检测2组患者治疗前、后血气分析指标、血液黏稠度及肺动脉压情况;记录2组患者痰液正常和发绀、咳嗽、湿啰音、水肿时间。结果治疗组治疗临床总有效率92.0%,明显高于对照组70.0%（P〈0.01）;治疗后,2组患者各项血液流变学指标、血气分析指标均较治疗前明显改善,治疗组各项指标改善程度均明显优于对照组（P〈0.05）。治疗后,治疗组肺动脉压为（18.36±7.38）mm Hg,明显低于对照组（23.79±6.14）mm Hg（P〈0.05）;2组治疗前肺动脉压均明显低于治疗前（P〈0.05）。治疗后,治疗组痰液正常和发绀、咳嗽、湿啰音、水肿时间均明显短于对照组（P〈0.05）。治疗期间2组患者均未发生明显不良反应。结论采用米力农注射液综合治疗肺心病合并呼吸衰竭患者疗效显著且安全,同时还可有助改善患者血液黏稠度和血气分析指标,降低肺动脉压,促进患者康复。

Objective To investigate the clinical effect of milrinone injection combined therapy in patients with cor pulmonale complicated with respiratory failure and observe the effect of milrinone on blood gas index,blood viscosity and pulmonary arterial pressure.Methods The clinical data of100 patients with cor pulmonale complicated with respiratory failure were retrospectively analyzed from April 2014 to April 2016.Among them,50 cases were treated with conventional oxygen therapy,diuretic,asthma and anti-infection treatment.In the control group,50 cases were treated with milrinone injection as the treatment group.The clinical curative effect and adverse reaction were analyzed.The blood gas analysis index,blood viscosity and pulmonary arterial pressure were measured before and after the treatment.The sputum normal and cyanosis,cough,wet rales and edema time were recorded in the two groups.Results The total effective rate of the treatment group was 92.0%,which was significantly higher than that of the control group 70.0%（P〈0.05）.After treatment,the hemorheological indexes and blood gas analysis indexes of the two groups improved significantly,However,the improvement of the indicators of the treatment group were significantly better than the control group（P〈0.05）.The pulmonary arterial pressure in the treatment group was（18.36±7.38） mm Hg,which was significantly lower than that in the control group（23.79±6.14） mm Hg（P〈0.05）;After treatment,the sputum normal and cyanosis in the treatment group,cough,wet rales,edema time were significantly shorter than the control group（P〈0.05）.No significant adverse effects were observed in both groups during the treatment.Conclusion The use of milrinone injection comprehensive treatment of pulmonary heart disease with respiratory failure in patients with significant efficacy and safety,but also can help improve blood viscosity and blood gas analysis indicators,reduce pulmonary artery pressure,better promote the rehabilitation of patients.